ADPT vs REGN: Which Stock is Better?
Side-by-side comparison of Adaptive Biotechnologies Corp and Regeneron Pharmaceuticals Inc in 2026
ADPT
Adaptive Biotechnologies Corp
$17.87
REGN
Regeneron Pharmaceuticals Inc
$733.78
Key Metrics Comparison
| Metric | ADPT | REGN | Winner |
|---|---|---|---|
| Market Cap | $2.67B | $77.69B | REGN |
| P/E Ratio | N/A | 17.57 | REGN |
| EPS (TTM) | $N/A | $41.71 | REGN |
| Revenue Growth | 1.0% | 0.0% | ADPT |
| Gross Margin | 65.1% | 45.8% | ADPT |
Analyze ADPT
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ADPT or REGN a better investment?
Comparing ADPT and REGN: Adaptive Biotechnologies Corp has a market cap of $2.67B while Regeneron Pharmaceuticals Inc has $77.69B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ADPT and REGN?
ADPT (Adaptive Biotechnologies Corp) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ADPT or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ADPT or REGN?
ADPT has higher revenue growth at 1.0% vs 0.0% for REGN.
Which company is more profitable: ADPT or REGN?
Adaptive Biotechnologies Corp (ADPT) has higher gross margins at 65.1% compared to 45.8% for REGN.
Which is the larger company: ADPT or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $77.69B compared to $2.67B for ADPT.
Should I buy ADPT or REGN in 2026?
Both ADPT and REGN have investment merit. ADPT trades at $17.87 while REGN trades at $733.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ADPT and REGN stock?
Key differences: Market Cap ($2.67B vs $77.69B), P/E Ratio (N/A vs 17.6x), Revenue Growth (1.0% vs 0.0%), Gross Margin (65.1% vs 45.8%).